TipRanks - 2025-06-17 13:20
B. Riley lowered the firm’s price target on MediciNova (MNOV) to $5 from $6 and keeps a Buy rating on the shares. The firm points out the company’s current cash on hand of $37M implies a runway into 2027. It updated MediciNova’s model, now exclusively focused on amyotrophic lateral sclerosis-related risk-adjusted revenue and spending. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >>